Resmed
ResMed Inc., a leading player in the sleep and respiratory care industry, is headquartered in the United States, with significant operations across Europe, Asia, and Australia. Founded in 1989, ResMed has consistently innovated in the development of cloud-connected devices and software solutions that enhance patient care and improve quality of life for those with sleep apnoea and chronic obstructive pulmonary disease (COPD). The company’s core offerings include advanced continuous positive airway pressure (CPAP) devices, portable oxygen concentrators, and digital health solutions, all designed to provide seamless integration and user-friendly experiences. ResMed's commitment to research and development has positioned it as a market leader, recognised for its pioneering technologies and significant contributions to the field of sleep medicine. With a strong focus on improving patient outcomes, ResMed continues to set benchmarks in the healthcare industry.
DitchCarbon Score
How does Resmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Resmed's score of 63 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Resmed's reported carbon emissions
In 2024, ResMed Inc., headquartered in the United States, reported total carbon emissions of approximately 25,059,000 kg CO2e. This figure includes about 3,743,000 kg CO2e from Scope 1 emissions and about 21,317,000 kg CO2e from Scope 2 emissions. In comparison, the previous year, 2023, saw total emissions of about 28,391,000 kg CO2e, with Scope 1 at approximately 4,453,000 kg CO2e and Scope 2 at around 23,939,000 kg CO2e. This indicates a reduction in total emissions from 2023 to 2024. ResMed has set ambitious climate commitments, aiming for a near-zero reduction in both Scope 1 and Scope 2 emissions by 2025. Additionally, the company has committed to a long-term target of reducing Scope 1 and Scope 2 emissions by 90% by 2050, using 2022 as the base year. Near-term targets include a 42% reduction in absolute Scope 1 and 2 GHG emissions by 2030. Furthermore, ResMed aims to reduce Scope 3 emissions by 51.6% per megawatt constructed within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect ResMed's commitment to achieving net-zero greenhouse gas emissions across its value chain by 2050. The company has demonstrated a proactive approach to sustainability, focusing on electrification opportunities and developing site emissions profiles to further enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Resmed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
